The global Eosinophilic Granulomatosis with Polyangiitis Treatment Market is currently valued at US$173.8 Million in 2023 and is anticipated to expand at a CAGR of 5.2%. Owing to the technological advances in healthcare the market is likely to propel to US$ 288.5 million by 2033.
The presence of a strong product pipeline and the imminent launches are likely to drive the growth of the Eosinophilic Granulomatosis with Polyangiitis Treatment Market in the forecast period.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 173.8 Million |
| Projected Forecast Value (2033) | US$ 288.5 Million |
| Global Growth Rate (2023-2033) | 5.2% CAGR |
Eosinophilic granulomatosis with polyangiitis (EGPA), formerly called Churg-Strauss syndrome, is a form of a vasculitis-a family of rare diseases characterized by inflammation of the blood vessels, which can restrict blood flow and damage vital organs and tissues. EGPA is one of the rarest forms of vasculitis and primarily affects the small blood vessels. Individuals diagnosed with EGPA usually have a history of asthma or allergies.
EGPA can affect the lungs, sinuses, skin, heart, intestinal tract, kidneys, nerves, and other organs. EGPA is known as ANCA-associated vasculitis, referring to a blood protein (anti-neutrophil cytoplasmic antibody) that attacks the body’s own cells and tissues. Other forms of ANCA-associated vasculitis include granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). The detection of ANCA in the blood can support a diagnosis of EGPA in some patients.
Treatment typically includes corticosteroids such as prednisone used in combination with medications that suppress the immune system. A new medication has been added to the treatment toolbox. In late 2017, the USA Food and Drug Administration (FDA) approved the use of the biological drug mepolizumab (Nucala) for the treatment of EGPA in adults in the United States.
EGPA is considered extremely rare, with an incidence in the United States of 1 to 3 cases per 100,000 adults per year. The international incidence of EGPA is estimated at 2.5 cases per 100,000 adults per year.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Growing Incidences of Churg Strauss Syndrome to Drive the Market Growth
With a significant rise in the number of eosinophils, which affects the immune system. With a tremendous rise, the condition affects the organs of the human body, resulting in a severe and fatal condition, if not treated. As a result, a large number of medications and therapeutics are available across the globe to treat this condition, which is expected to encourage the growth of the global eosinophilic granulomatosis with polyangiitis treatment market in the next few years.
The growing occurrences of church Strauss syndrome and other allergic reactions and asthma, the rising geriatric population, and growing incidences of church Strauss syndrome in children are expected to drive the growth of the market during the assessment period.
The rising focus of the prominent players operating in the global eosinophilic granulomatosis with polyangiitis treatment market on the development of new and effective treatments and the increasing expenditure on research and development activities are projected to accelerate the growth of the overall market in the next few years. Furthermore, the rising support from government organizations and the development of healthcare facilities and infrastructure are projected to supplement the development of the overall market in the forecast period.
Increasing Research & Development Activities to Boost The Market Growth
The increasing awareness among patients regarding this condition and the availability of effective therapeutics are projected to bolster the eosinophilic granulomatosis with polyangiitis treatment market in developed economies
Increasing government expenditure for sinus pain and inflammation, a large number of people visiting doctors for allergic reaction problems,s and an increase in research and development activities are likely to create various new opportunities that will impact eosinophilic granulomatosis with polyangiitis treatment market growth in the forecast period of 2023 to 2033.
The development of modern therapeutics and the increasing number of players with a strong drug pipeline is considered the key factors that are likely to contribute substantially towards the development of the global eosinophilic granulomatosis with polyangiitis treatment market in the next few years.
Lack of Awareness Regarding Eosinophilic Granulomatosis with Polyangiitis Restrain the Market Growth
One of the major factors hindering the growth of the eosinophilic granulomatosis with polyangiitis treatment market over the analysis period includes the lack of awareness regarding the disease. The high cost of therapeutics is another factor that is expected to impede the market growth.
The lack of knowledge and the absence of required healthcare infrastructure are estimated to restrict the growth of the market, particularly in developing economies in the next few years.
The unfavorable reimbursement scenario in many developing countries and the lack of awareness regarding autoimmune disorders in people can hinder the growth of the market during the forecast period. Also, no specific tests available for diagnosis of eosinophilic granulomatosis with polyangiitis can challenge the growth of the target market in the above-mentioned forecast period.
Principal Consultant
Advancement in Healthcare to Boost the Market Growth in Region
North America dominates the eosinophilic granulomatosis with polyangiitis treatment market with a CAGR of 5.1% in 2023. The market growth in this region is attributed to the increasing number of asthma patients, changes in environmental conditions, increasing allergic reactions, and others. Moreover, the increasing incidence of asthma in the aging population is expected to fuel the growth of the market in this region.
The growing prevalence of autoimmune diseases and endocrine disorders is the primary factor driving the growth of these regions. The rising awareness regarding the malignant effects of eosinophilic granulomatosis with polyangiitis and the development of modern therapies for its treatment and drug approvals are providing a fillip to the market in these regions.
For instance, Roche announced that the USA Food and Drug Administration (FDA) has approved Rituxan® (rituximab), in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in pediatric patients 2 years of age and older. GPA and MPA are rare, potentially life-threatening diseases affecting small and medium-sized blood vessels.
Improvement in healthcare spending propelling the growth of Eosinophilic Granulomatosis with Polyangiitis Treatment in Asia Pacific
Asia-Pacific is anticipated to be the fastest-growing market owing to the growing prevalence of immunosuppressant disease and hyper-eosinophilia-related problems in developing countries and increasing incidences of granulomatosis.
Asia Pacific is expected to witness tremendous growth during the forecast period, due to favorable reimbursement policies and the presence of policies that offer tax benefits. Factors such as expanding the patient base, improving healthcare infrastructure, and increasing the incidence of anemia are also influencing the growth of the region positively.
Country-wise Forecast CAGRs for the Eosinophilic Granulomatosis with Polyangiitis Treatment Market
| United Kingdom | 5.0% |
|---|---|
| India | 4.9% |
| South Korea | 4.5% |
| China | 4.8% |
| United States of America | 5.1% |
Hospital Pharmacy Segment Remains Dominant Among Other Types
The hospital pharmacy segment dominated the global market in 2023 with a revenue share of over 35.7%. The growth of the segment is attributed to the increasing prevalence of church Strauss syndrome and hospitalization for treatment.
Hospital pharmacies preserve the stock of products related to eosinophilic granulomatosis with polyangiitis for out-patients as well as in-patients. The segment will be driven further by growing consumer awareness and increased investments in healthcare infrastructure in developing and underdeveloped countries.
The online pharmacies segment is expected to be the fastest-growing distribution channel segment. This growth can be attributed to user-friendly interfaces and convenience offered by these pharmacies, in terms of access, prices, and delivery. In addition, they have several discounts on purchases of a certain amount or offer bundle pricing for many products.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
With technological innovations happening at a rapid pace, and companies looking for ways to increase customer engagement, start-ups are taking all possible steps to establish a name for themselves in the eosinophilic granulomatosis with polyangiitis treatment market.
Some of the start-ups in the eosinophilic granulomatosis with polyangiitis treatment market include-
Some of the key players present in the global eosinophilic granulomatosis with polyangiitis treatment markets are Genentech Inc., F. Hoffmann-La Roche AG, Cephalon Inc., Teva Pharmaceutical Industries Ltd., Amgen Inc., Sanofi S.A., Koninklijke DSM N.V, AstraZeneca, Novartis International AG, GlaxoSmithKline LLC, Baxter Healthcare Corporation and others.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, applications, and industries.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR 5.2% from 2023 to 2033 |
| Expected Market Value (2023) | US$ 173.8 Million |
| Projected Forecast Value (2033) | US$ 288.5 Million |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion & CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends & Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The projected CAGR of the market by 2033 is 5.2%.
The projected market value for 2033 is US$ 288.5 million.
The market is estimated to secure a valuation of US$ 173.8 million in 2023.
The healthcare industry is the key consumer of the market.
The market is growing due to the increasing availability of effective treatments.
1. Executive Summary | Eosinophilic Granulomatosis with Polyangiitis Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
5.3.1. Steroids
5.3.2. Immunosuppressant
5.3.3. Biologics
5.3.4. Immune Globulins
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
6.3.1. Oral
6.3.2. Intravenous
6.3.3. Intramuscular
6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channels
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channels, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channels, 2023 to 2033
7.3.1. Hospital Pharmacies
7.3.2. Drug Stores
7.3.3. Retail Pharmacies
7.3.4. Online Pharmacies
7.4. Y-o-Y Growth Trend Analysis By Distribution Channels, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Distribution Channels, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. Middle East & Africa (MEA)
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Drug Class
9.2.3. By Route of Administration
9.2.4. By Distribution Channels
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Route of Administration
9.3.4. By Distribution Channels
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Drug Class
10.2.3. By Route of Administration
10.2.4. By Distribution Channels
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Route of Administration
10.3.4. By Distribution Channels
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. UK
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Drug Class
11.2.3. By Route of Administration
11.2.4. By Distribution Channels
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Route of Administration
11.3.4. By Distribution Channels
11.4. Key Takeaways
12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Drug Class
12.2.3. By Route of Administration
12.2.4. By Distribution Channels
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Route of Administration
12.3.4. By Distribution Channels
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Drug Class
13.2.3. By Route of Administration
13.2.4. By Distribution Channels
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Route of Administration
13.3.4. By Distribution Channels
13.4. Key Takeaways
14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Drug Class
14.2.3. By Route of Administration
14.2.4. By Distribution Channels
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Class
14.3.3. By Route of Administration
14.3.4. By Distribution Channels
14.4. Key Takeaways
15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Drug Class
15.2.3. By Route of Administration
15.2.4. By Distribution Channels
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Drug Class
15.3.3. By Route of Administration
15.3.4. By Distribution Channels
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Drug Class
16.1.2.2. By Route of Administration
16.1.2.3. By Distribution Channels
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Drug Class
16.2.2.2. By Route of Administration
16.2.2.3. By Distribution Channels
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Drug Class
16.3.2.2. By Route of Administration
16.3.2.3. By Distribution Channels
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Drug Class
16.4.2.2. By Route of Administration
16.4.2.3. By Distribution Channels
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Drug Class
16.5.2.2. By Route of Administration
16.5.2.3. By Distribution Channels
16.6. UK
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Drug Class
16.6.2.2. By Route of Administration
16.6.2.3. By Distribution Channels
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Drug Class
16.7.2.2. By Route of Administration
16.7.2.3. By Distribution Channels
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Drug Class
16.8.2.2. By Route of Administration
16.8.2.3. By Distribution Channels
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Drug Class
16.9.2.2. By Route of Administration
16.9.2.3. By Distribution Channels
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Drug Class
16.10.2.2. By Route of Administration
16.10.2.3. By Distribution Channels
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Drug Class
16.11.2.2. By Route of Administration
16.11.2.3. By Distribution Channels
16.12. Singapore
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Drug Class
16.12.2.2. By Route of Administration
16.12.2.3. By Distribution Channels
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Drug Class
16.13.2.2. By Route of Administration
16.13.2.3. By Distribution Channels
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Drug Class
16.14.2.2. By Route of Administration
16.14.2.3. By Distribution Channels
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Drug Class
16.15.2.2. By Route of Administration
16.15.2.3. By Distribution Channels
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Drug Class
16.16.2.2. By Route of Administration
16.16.2.3. By Distribution Channels
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Drug Class
16.17.2.2. By Route of Administration
16.17.2.3. By Distribution Channels
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Drug Class
16.18.2.2. By Route of Administration
16.18.2.3. By Distribution Channels
16.19. GCC Countries
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Drug Class
16.19.2.2. By Route of Administration
16.19.2.3. By Distribution Channels
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Drug Class
16.20.2.2. By Route of Administration
16.20.2.3. By Distribution Channels
16.21. Israel
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Drug Class
16.21.2.2. By Route of Administration
16.21.2.3. By Distribution Channels
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Drug Class
17.3.3. By Route of Administration
17.3.4. By Distribution Channels
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Genentech Inc.
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. F. Hoffmann-La Roche AG
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Cephalon Inc.
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Teva Pharmaceutical Industries Ltd.
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Amgen Inc.
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Sanofi S.A.
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Koninklijke DSM N.V
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. AstraZeneca
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Novartis International AG
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. GlaxoSmithKline LLC
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
18.1.11. Baxter Healthcare Corporation
18.1.11.1. Overview
18.1.11.2. Product Portfolio
18.1.11.3. Profitability by Market Segments
18.1.11.4. Sales Footprint
18.1.11.5. Strategy Overview
18.1.11.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Eosinophilic Granulomatosis with Polyangiitis Treatment Market
